Anti-Mouse CD31 (PECAM-1) – FITC

Mouse 32D leukocyte cell line

This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

Blue Laser (488 nm)

390 activity is directed against mouse CD31 (PECAM-1).

PECAM-1 was the first immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptor to be identified in platelets and acts as a negative regulator of platelet activation¹. Platelet activation from a resting state has broad implications for many pathophysiological processes including anthogenesis, angiogenesis, inflammation, wound repair, and cancer metastasis. PECAM-1 inhibits platelet activation and thrombosis at sites of vascular injury by attenuating immunoreceptor tyrosine-based activation motif (ITAM)-containing receptor complex GPVI-FcR γ-chain signaling and by acting as a positive regulator of α_IIbβ₃-mediated outside-in signaling. PECAM-1, like all ITIM-containing receptors, belongs to the immunoglobulin receptor superfamily.

PECAM-1 also functions as a cell adhesion molecule and is capable of mediating calcium- dependent heterophilic aggregation². Additionally, PECAM-1 is expressed at cell-cell borders in the endocardial cells of the developing murine heart³. Because of its distribution pattern, PECAM-1 is a target molecule for the delivery of antithrombotic agents^4,5,6,7. Research is being conducted into the ability of PECAM-1 to deliver drugs to the endothelium.

Clone 390 was generated by immunizing rats with mouse 32D leukocyte cell line and screening against muPECAM-1Δ12,15^3,8. 390 binds to an epitope on Ig-domain 2 of muPECAM-1^7,9.

PECAM-1 is expressed on the majority of non-erythroid hematopoietic cells, including platelets, monocytes, neutrophils, T cells, and B cell subsets, as well as on vascular endothelium and the endocardial cells of developing heart tissue.

CD38, αV/β3 integrin

1 Coxon CH, Geer MJ, Senis YA. Blood. 129(26):3407-3418. 2017.
2 DeLisser HM, Yan HC, Newman PJ, et al. J Biol Chem. 268(21):16037-16046. 1993.
3 Baldwin HS, Shen HM, Yan HC, et al. Development. 120(9):2539-2553. 1994.
4 Muzykantov VR, Christofidou-Solomidou M, Balyasnikova I, et al. Proc Natl Acad Sci U S A. 96(5):2379-2384. 1999.
5 Scherpereel A, Wiewrodt R, Christofidou-Solomidou M, et al. FASEB J. 15(2):416-426. 2001.
6 Ding BS, Gottstein C, Grunow A, et al. Blood. 106(13):4191-4198. 2005.
7 Chacko AM, Nayak M, Greineder CF, et al. PLoS One. 7(4):e34958. 2012.
8 Yan HC, Baldwin HS, Sun J, et al. J Biol Chem. 270(40):23672-23680. 1995.
9 Nakada MT, Amin K, Christofidou-Solomidou M, et al. J Immunol. 164(1):452-462. 2000.
10 DeLisser HM, Newman PJ, Albelda SM. Immunol Today. 15(10):490-495. 1994.
11 Wee JL, Jackson DE. Blood. 106(12):3816-3823. 2005.
12 Fu T, Sullivan DP, Gonzalez AM, et al. Immunity. 56(10):2311-2324.e6. 2023.